R1 RCM (NASDAQ:RCM) Releases Earnings Results, Misses Expectations By $0.03 EPS

R1 RCM (NASDAQ:RCM - Get Free Report) announced its quarterly earnings data on Wednesday. The healthcare provider reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.03), Briefing.com reports. R1 RCM had a return on equity of 0.12% and a net margin of 0.15%. The company had revenue of $603.90 million for the quarter, compared to analysts' expectations of $612.88 million. The company's revenue for the quarter was up 10.7% compared to the same quarter last year. R1 RCM updated its FY 2024 guidance to EPS.

R1 RCM Trading Down 4.4 %

Shares of RCM traded down $0.57 on Thursday, hitting $12.27. 9,101,789 shares of the stock traded hands, compared to its average volume of 3,537,086. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.83 and a current ratio of 1.83. The stock's 50 day moving average is $12.88 and its two-hundred day moving average is $11.46. R1 RCM has a 1 year low of $8.87 and a 1 year high of $18.70.

Insider Activity at R1 RCM

In other R1 RCM news, President John M. Sparby sold 10,046 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $14.33, for a total transaction of $143,959.18. Following the transaction, the president now owns 265,986 shares of the company's stock, valued at $3,811,579.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 36.80% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Guggenheim reduced their target price on R1 RCM from $17.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, April 5th. Barclays reaffirmed an "equal weight" rating and issued a $14.00 price objective on shares of R1 RCM in a research note on Wednesday, February 28th. Truist Financial reaffirmed a "hold" rating and issued a $16.00 price objective on shares of R1 RCM in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of R1 RCM in a research note on Wednesday, April 10th. Finally, KeyCorp reaffirmed a "sector weight" rating on shares of R1 RCM in a research note on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.71.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.